Cargando…

Association of CSF proteins with tau and amyloid β levels in asymptomatic 70-year-olds

BACKGROUND: Increased knowledge of the evolution of molecular changes in neurodegenerative disorders such as Alzheimer’s disease (AD) is important for the understanding of disease pathophysiology and also crucial to be able to identify and validate disease biomarkers. While several biological change...

Descripción completa

Detalles Bibliográficos
Autores principales: Remnestål, Julia, Bergström, Sofia, Olofsson, Jennie, Sjöstedt, Evelina, Uhlén, Mathias, Blennow, Kaj, Zetterberg, Henrik, Zettergren, Anna, Kern, Silke, Skoog, Ingmar, Nilsson, Peter, Månberg, Anna
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7923505/
https://www.ncbi.nlm.nih.gov/pubmed/33653397
http://dx.doi.org/10.1186/s13195-021-00789-5
_version_ 1783658916610048000
author Remnestål, Julia
Bergström, Sofia
Olofsson, Jennie
Sjöstedt, Evelina
Uhlén, Mathias
Blennow, Kaj
Zetterberg, Henrik
Zettergren, Anna
Kern, Silke
Skoog, Ingmar
Nilsson, Peter
Månberg, Anna
author_facet Remnestål, Julia
Bergström, Sofia
Olofsson, Jennie
Sjöstedt, Evelina
Uhlén, Mathias
Blennow, Kaj
Zetterberg, Henrik
Zettergren, Anna
Kern, Silke
Skoog, Ingmar
Nilsson, Peter
Månberg, Anna
author_sort Remnestål, Julia
collection PubMed
description BACKGROUND: Increased knowledge of the evolution of molecular changes in neurodegenerative disorders such as Alzheimer’s disease (AD) is important for the understanding of disease pathophysiology and also crucial to be able to identify and validate disease biomarkers. While several biological changes that occur early in the disease development have already been recognized, the need for further characterization of the pathophysiological mechanisms behind AD still remains. METHODS: In this study, we investigated cerebrospinal fluid (CSF) levels of 104 proteins in 307 asymptomatic 70-year-olds from the H70 Gothenburg Birth Cohort Studies using a multiplexed antibody- and bead-based technology. RESULTS: The protein levels were first correlated with the core AD CSF biomarker concentrations of total tau, phospho-tau and amyloid beta (Aβ42) in all individuals. Sixty-three proteins showed significant correlations to either total tau, phospho-tau or Aβ42. Thereafter, individuals were divided based on CSF Aβ42/Aβ40 ratio and Clinical Dementia Rating (CDR) score to determine if early changes in pathology and cognition had an effect on the correlations. We compared the associations of the analysed proteins with CSF markers between groups and found 33 proteins displaying significantly different associations for amyloid-positive individuals and amyloid-negative individuals, as defined by the CSF Aβ42/Aβ40 ratio. No differences in the associations could be seen for individuals divided by CDR score. CONCLUSIONS: We identified a series of transmembrane proteins, proteins associated with or anchored to the plasma membrane, and proteins involved in or connected to synaptic vesicle transport to be associated with CSF biomarkers of amyloid and tau pathology in AD. Further studies are needed to explore these proteins’ role in AD pathophysiology. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13195-021-00789-5.
format Online
Article
Text
id pubmed-7923505
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-79235052021-03-02 Association of CSF proteins with tau and amyloid β levels in asymptomatic 70-year-olds Remnestål, Julia Bergström, Sofia Olofsson, Jennie Sjöstedt, Evelina Uhlén, Mathias Blennow, Kaj Zetterberg, Henrik Zettergren, Anna Kern, Silke Skoog, Ingmar Nilsson, Peter Månberg, Anna Alzheimers Res Ther Research BACKGROUND: Increased knowledge of the evolution of molecular changes in neurodegenerative disorders such as Alzheimer’s disease (AD) is important for the understanding of disease pathophysiology and also crucial to be able to identify and validate disease biomarkers. While several biological changes that occur early in the disease development have already been recognized, the need for further characterization of the pathophysiological mechanisms behind AD still remains. METHODS: In this study, we investigated cerebrospinal fluid (CSF) levels of 104 proteins in 307 asymptomatic 70-year-olds from the H70 Gothenburg Birth Cohort Studies using a multiplexed antibody- and bead-based technology. RESULTS: The protein levels were first correlated with the core AD CSF biomarker concentrations of total tau, phospho-tau and amyloid beta (Aβ42) in all individuals. Sixty-three proteins showed significant correlations to either total tau, phospho-tau or Aβ42. Thereafter, individuals were divided based on CSF Aβ42/Aβ40 ratio and Clinical Dementia Rating (CDR) score to determine if early changes in pathology and cognition had an effect on the correlations. We compared the associations of the analysed proteins with CSF markers between groups and found 33 proteins displaying significantly different associations for amyloid-positive individuals and amyloid-negative individuals, as defined by the CSF Aβ42/Aβ40 ratio. No differences in the associations could be seen for individuals divided by CDR score. CONCLUSIONS: We identified a series of transmembrane proteins, proteins associated with or anchored to the plasma membrane, and proteins involved in or connected to synaptic vesicle transport to be associated with CSF biomarkers of amyloid and tau pathology in AD. Further studies are needed to explore these proteins’ role in AD pathophysiology. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13195-021-00789-5. BioMed Central 2021-03-02 /pmc/articles/PMC7923505/ /pubmed/33653397 http://dx.doi.org/10.1186/s13195-021-00789-5 Text en © The Author(s) 2021 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Remnestål, Julia
Bergström, Sofia
Olofsson, Jennie
Sjöstedt, Evelina
Uhlén, Mathias
Blennow, Kaj
Zetterberg, Henrik
Zettergren, Anna
Kern, Silke
Skoog, Ingmar
Nilsson, Peter
Månberg, Anna
Association of CSF proteins with tau and amyloid β levels in asymptomatic 70-year-olds
title Association of CSF proteins with tau and amyloid β levels in asymptomatic 70-year-olds
title_full Association of CSF proteins with tau and amyloid β levels in asymptomatic 70-year-olds
title_fullStr Association of CSF proteins with tau and amyloid β levels in asymptomatic 70-year-olds
title_full_unstemmed Association of CSF proteins with tau and amyloid β levels in asymptomatic 70-year-olds
title_short Association of CSF proteins with tau and amyloid β levels in asymptomatic 70-year-olds
title_sort association of csf proteins with tau and amyloid β levels in asymptomatic 70-year-olds
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7923505/
https://www.ncbi.nlm.nih.gov/pubmed/33653397
http://dx.doi.org/10.1186/s13195-021-00789-5
work_keys_str_mv AT remnestaljulia associationofcsfproteinswithtauandamyloidblevelsinasymptomatic70yearolds
AT bergstromsofia associationofcsfproteinswithtauandamyloidblevelsinasymptomatic70yearolds
AT olofssonjennie associationofcsfproteinswithtauandamyloidblevelsinasymptomatic70yearolds
AT sjostedtevelina associationofcsfproteinswithtauandamyloidblevelsinasymptomatic70yearolds
AT uhlenmathias associationofcsfproteinswithtauandamyloidblevelsinasymptomatic70yearolds
AT blennowkaj associationofcsfproteinswithtauandamyloidblevelsinasymptomatic70yearolds
AT zetterberghenrik associationofcsfproteinswithtauandamyloidblevelsinasymptomatic70yearolds
AT zettergrenanna associationofcsfproteinswithtauandamyloidblevelsinasymptomatic70yearolds
AT kernsilke associationofcsfproteinswithtauandamyloidblevelsinasymptomatic70yearolds
AT skoogingmar associationofcsfproteinswithtauandamyloidblevelsinasymptomatic70yearolds
AT nilssonpeter associationofcsfproteinswithtauandamyloidblevelsinasymptomatic70yearolds
AT manberganna associationofcsfproteinswithtauandamyloidblevelsinasymptomatic70yearolds